For Pharma
Intervention, continuous physiology, and outcome, captured at the same time. This is the dose-response evidence pharma spends roughly $2.3 billion per approved drug trying to generate, and it has never been collected this way.
The evidence gap
Drug development can prove that a molecule is safe and effective in a trial. What it cannot show is how the body actually responds, dose by dose, once the drug leaves the controlled setting. The continuous physiological response is the missing variable, and it is the variable that decides real-world value.
EHR claims and chart data capture what was prescribed, not how the body responded to it.
Trial data ends at study close and rarely includes continuous, between-visit physiology.
How Bardel solves it
Trak+ is the intelligence layer that captures the physiological signal others miss, from a phone camera, a watch, a chest strap, or a clinical monitor. Every therapeutic session writes a single linked record: what was given, how the body responded in real time, and what happened next. That linkage is the asset.
The treatment, the dose, and the timing, captured as given, not recalled later.
The body's response between visits, read as a structured signal, not just its volume.
The result the response produced, tied back to the exact intervention that drove it.
one continuous dose-response record
The capability
Bardel captures the phenotype as a baseline, measures the change in real time, and reveals the pattern across a course of therapy. The result is a complete picture of how the body is responding, and every read returns a clear answer: strong responder, moderate, non-responder, or adverse.
Use cases
Show how the body responds across the real dosing range and the real patient mix, not just the narrow window a trial protocol allows. The continuous response curve that simulation and chart review can only approximate.
Watch how a marketed therapy performs in the field, session by session, and surface non-response and adverse patterns early enough to inform clinicians and protect the franchise.
Define and recruit cohorts by how patients actually respond, not by proxy criteria. Enrich studies with objective, between-visit physiology that the existing toolkit cannot reach.
Why it is defensible
Real-world evidence is already one of the most valuable assets in medicine, and the companies that built it did so on data that records what was prescribed, not how the body responded. Bardel captures something those sources structurally cannot: the body's continuous response, linked to the exact intervention that drove it.
The opportunity
Bardel partners with pharma to make the dose-response dataset answer real commercial and clinical questions, scoped to the therapeutic area and the depth of the response window that matters to you. As the platform grows across devices, states, and sessions, the evidence does not just get bigger. It gets richer, and every new record raises the value of the rest.
therapeutic sessions captured to date, each one a linked intervention, response, and outcome record, with the dataset growing across 33 states.
Proof and partnership
This is not a thesis on a slide. The platform is live, the science is peer-reviewed, and the dataset is being captured in the field as of 2026.
Advised by
Pharma commercialization advisor. Led the U.S. Ozempic launch at Novo Nordisk, and former VP, Global Commercial at Johnson & Johnson. He knows exactly what evidence moves a franchise, and which evidence has never existed.
See the platform, or open a conversation about the dose-response dataset for your therapeutic area.